Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. has announced the completion of nearly RMB 100 million in Series C financing, with the Qingke Industrial Investment Fund under Qingke Group as the exclusive investor. Sanyou Biopharmaceuticals is a high-tech enterprise dedicated to innovative drug R&D and commercialization. Having previously completed multiple rounds of financing, this round represents a significant milestone in the company's development. The company has established three core platforms: the intelligent ultra-trillion molecular library AI-STAL, the dry-wet integrated intelligent new drug accelerator SAI-DA, and the original innovative drug co-creation platform Clicklinks. Driven by a three-pronged strategy of "source innovation + intelligent acceleration + pipeline-driven," the company breaks through the bottleneck of source innovation in new drugs and connects the entire chain of preclinical R&D. To date, the company has partnered with more than 2,000 pharmaceutical and biotechnology companies worldwide, completed over 100 collaborative R&D projects, and seen more than ten innovative drug projects enter the clinical research stage. This round of financing will accelerate the enhancement of the company's AI-driven business system and advance its upgrade toward pipeline-based, platform-based, and systematized innovative drug innovation and transformation capabilities. Looking ahead, the company will continue to strengthen the development of its core platforms, focus on new drug transformation, and work with partners to improve the overall efficiency of innovative drug R&D and unlock industrial value. Dr. Lang Guojun, founder and CEO of Sanyou Biopharmaceuticals, and relevant executives from Qingke Group shared their perspectives on this financing and industry development.